THE AFFILIATED HOSPITAL OF QINGDAO UNIVERSITY
🇨🇳China
PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 30
- Registration Number
- NCT04284202
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, China
Real World Study of Four PD-1 Agents in China
- Conditions
- Thoracic CancerGynecologic CancerAbdomen TumorsMalignant Melanoma
- Interventions
- Drug: Chemotherapy
- First Posted Date
- 2019-05-29
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 500
- Registration Number
- NCT03966456
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034）
Phase 2
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 46
- Registration Number
- NCT03735264
Study for Patients With Lung Metastatic Advanced Gastric Cancer and NSCLC Treated With Apatinib
Completed
- Conditions
- Lung CancerGastric Cancer Metastatic to Lung
- Interventions
- Other: lung cavitation
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 187
- Registration Number
- NCT03629691
© Copyright 2025. All Rights Reserved by MedPath